Navigation Links
Poniard Pharmaceuticals Provides Year-End Clinical Update at 2007 Lazard Capital Markets Healthcare Conference
Date:11/27/2007

- Significant clinical progress noted in small cell lung, prostate and

colorectal cancer trials -

SOUTH SAN FRANCISCO, Calif., Nov. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today provided an update of its picoplatin development program in small cell lung cancer (SCLC), colorectal cancer (CRC) and hormone refractory prostate cancer (HRPC), and its oral formulation in solid tumors. Presenting at the Lazard Capital Markets Healthcare Conference in New York, Jerry McMahon, Ph.D., chairman and CEO of Poniard, noted that the Company has made significant progress in 2007 in its clinical development program for picoplatin, its lead product candidate.

"2007 has been an important year for Poniard, as we have continued to advance our development of picoplatin, a new generation chemotherapy agent with the potential to become a platform product addressing multiple indications, combinations and formulations," said Dr. McMahon. "We continue to drive our clinical programs toward completion and have achieved significant milestones this year. In addition, we remain on track to file our NDA for picoplatin in 2009."

Poniard is providing an update on the progress on all four of its picoplatin clinical trials, as follows:

Phase 3 SPEAR Trial:

Poniard is evaluating intravenous picoplatin in an ongoing pivotal Phase 3 trial, known as SPEAR (Study of Picoplatin Efficacy After Relapse), in SCLC. This registrational trial is being conducted under a Special Protocol Assessment (SPA) from the U.S. Food and Drug Administration (FDA) and is evaluating overall survival as the primary endpoint.

To date
'/>"/>

SOURCE Poniard Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
2. Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
3. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Initiates Randomized Phase 2 Trial of Picoplatin for First-Line Treatment of Metastatic Colorectal Cancer
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
(Date:10/18/2014)... WASHINGTON , Oct. 18, 2014  In ... Human Rights Campaign (HRC), the nation,s largest lesbian, ... explicitly endorsed the use of Truvada for Pre-Exposure ... health tool used to prevent the spread of ... is the only brand name anti-HIV drug combination ...
Breaking Medicine Technology:Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 2HRC Endorses PrEP, Calls for Bold Action to Expand Access to Anti-HIV Drug 3
... Johnson Pharmaceutical,Research & Development, L.L.C. (J&JPRD), today ... doripenem for injection), a,carbapenem antibiotic, was found ... certain,strains of Enterobacteriaceae, including Extended-spectrum Beta-lactamases,(ESBLs) than ... a large group of bacteria that can ...
... Data Shows Long-term Improvements in Productivity, Quality of ... American College ... Oct. 27 5:00 AM PST -- UCB announced,today ... pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor),- ...
Cached Medicine Technology:New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 2New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 3New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 4New Data Show In Vitro Potency of Doripenem Against Resistant Bacteria 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 2CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 3CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 4CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 5CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 6CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 7CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 8CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 9CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years 10
(Date:10/20/2014)... Portland, Oregon (PRWEB) October 20, 2014 Succeed ... 16% of local companies who participated in the Every ... Walk! is a public awareness project that encourages workers to ... the Summer Step 10,000 Program, which concluded at the end ... wide variety of cities and metro areas. Participating companies ...
(Date:10/20/2014)... 20, 2014 Unveiled at the Sept. 18 ... Scorecard conservatively estimates member hospital ROI on membership dues at ... The Center provides $12.50 in value to member hospitals. The ... – Member Dues)/Member Dues. , “This is the first ... and we think the methodology is really sound,” said ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Do you ... interventions? Here comes a wonderful app Metassessor for teachers, ... development company helped its client “Intervention Development LLC” ... The app is designed for iOS 4.3 or later ... This app is optimized for iPhone 5. It is ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
Breaking Medicine News(10 mins):Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
... CAMPAIGN "KICK ONE, PICK ONE" ENCOURAGING ... AND SPEND TIME TOGETHER, NEW YORK, Dec. 20 ... Nite announces the launch of "Kick One, Pick One",(KOPO), the ... fit and spend more time together. Bowing Jan. 1, KOPO ...
... Medical College of Georgia has again been designated by ... Oncology Program. , The renewal, which comes with a ... latest cancer treatment and prevention strategies for all cancer ... the MCG section of Hematology/Oncology and principal investigator on ...
... boosted the odds by 67%, study found , THURSDAY, Dec. ... an abortion are much more likely than women who haven,t ... new research shows. , A team at Virginia Commonwealth University ... in the United States Collaborative Perinatal Project. , About 40 ...
... -- A Las Vegas business and Oak Ridge National Laboratory ... dehydration or congestive heart failure. , The task for ORNL ... improve and miniaturize Noninvasive Medical Technologies ZOE, a medical device ... is of great importance to members of the military and ...
... for runners who struggle to increase their pace, cyclists who ... their strokes. Researchers from the University of Exeter and Kansas ... our muscles when we push ourselves during exercise. , ... as the critical power. This level can increase as we ...
... years after patients were given Nobel Direct dental implants, the ... follow-up by researchers at the Sahlgrenska Academy in Sweden shows ... , Nobel Direct was launched in 2004 by Nobel Biocare ... could be screwed directly into the jawbone without having to ...
Cached Medicine News:Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 2Health News:Nick at Nite Asks Families to Kick a Bad Habit, Pick a Good One in 2008 3Health News:MCG receives second-time designation from National Cancer Institute 2Health News:MCG receives second-time designation from National Cancer Institute 3Health News:Prior Miscarriage Raises Risk for Low-Birthweight Infant 2Health News:Nevada company, ORNL develop potential lifesaver 2Health News:Why exertion leads to exhaustion 2Health News:Gloomy forecast for Nobel Direct after 3 years 2
... is the most advanced means of documenting ... management system that acquires extremely high quality ... can be captured directly from slit lamps ... well as any other ophthalmic device with ...
... device that replaces the old technology, the ... by bringing virtually unlimited charts to the ... are at the practitioners finger tips. The ... charts, optotypes, associated vision tests and fixation ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
... Two mirrored surfaces, which each incline ... front surface, have been cut into the ... it possible to examine the opposite iridocorneal ... expanse and form of the angle of ...
Medicine Products: